ECB May Stop Rate Hikes After December, Capital Economics Says 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
HUTCHMED, AstraZeneca Seek FDA Approval for Lung Cancer Combo 
TSMC Accelerates 2nm Expansion as AI Chip Demand Surges 
Nvidia China Chip Sales Report Sends Chinese Semiconductor Stocks Lower 
South Korea Exports Set for 16th Monthly Gain on AI Chip Demand 
Robinhood Chain Token Ring Allegedly Extracts $18.4 Million Across 53 Launches 
Strategy Buys 1,665 Bitcoin as BTC Holdings Reach 847,666 
South Korea Tax Windfall Could Top 50 Trillion Won on Chip Boom 
BitMine Ethereum Holdings Top 6 Million ETH After $46 Million Purchase 
RBA Hikes Interest Rate to 4.60% as Inflation Risks Rise 
Nissan Targets US Hybrid Growth With Rogue e-Power Launch 
Oil Prices Jump Nearly 3% as Iran Holds Firm on Hormuz Conditions 
Toyota Global Sales Fall for Seventh Month as China Demand Slumps 
Bitget Resumes Crypto Withdrawals After $388M Security Breach 
Northern Star Shares Surge After Rejecting Gold Fields Takeover Bid 
U.S. Stock Futures Fall as Iran, Oil and AI Risks Rattle Markets 
Add as a preferred source on Google
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
